免疫治疗联合放化疗治疗非小细胞肺癌的临床研究进展

摘要/Abstract

摘要：

放疗、化疗、免疫治疗三者间具有协同作用,随着免疫检查点抑制剂的临床应用,其联合放疗或放化疗治疗非小细胞肺癌显示出较好的近期、远期疗效,安全可靠。

林先勇, 胡翔, 殷海涛. 免疫治疗联合放化疗治疗非小细胞肺癌的临床研究进展[J]. 国际肿瘤学杂志, 2022, 49(1): 56-60.

Lin Xianyong, Hu Xiang, Yin Haitao. Clinical research progress of immunotherapy combined with chemoradiotherapy in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(1): 56-60.

参考文献33

[1]	Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98. DOI: 10.1056/NEJMoa011954. doi:10.1056/NEJMoa011954
[2]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi:10.1056/NEJMoa1606774
[3]	Britschgi C, Riesterer O, Burger IA, et al. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer[J]. Radiat Oncol, 2018, 13(1):102. DOI: 10.1186/s13014-018-1049-3. doi:10.1186/s13014-018-1049-3
[4]	白馨雅, 张金梦, 孙洋, 等. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8):500-504. DOI: 10.3760/cma.j.issn.1673-422X.2019.08.012. doi:10.3760/cma.j.issn.1673-422X.2019.08.012
[5]	Yamaguchi O, Kaira K, Hashimoto K, et al. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab[J]. Thorac Cancer, 2019, 10(4):992-1000. DOI: 10.1111/1759-7714.13044. doi:10.1111/1759-7714.13044pmid:30888716
[6]	Fiorica F, Belluomini L, Stefanelli A, et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination[J]. Am J Clin Oncol, 2018, 41(11):1101-1105. DOI: 10.1097/COC.0000000000000428. doi:10.1097/COC.0000000000000428
[7]	Bassanelli M, Ricciuti B, Giannarelli D, et al. Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study[J]. Tumori, 2021, 30089162-11004733. DOI: 10.1177/03008916211004733. doi:10.1177/03008916211004733
[8]	Tamiya A, Tamiya M, Nakahama K, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer[J]. Anticancer Res, 2017, 37(9):5199-5205. DOI: 10.21873/anticanres.11943. doi:10.21873/anticanres.11943
[9]	Furuta H, Yoshida T, Shimizu J, et al. Nivolumab enhances the inflammation of the irradiation field in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(11):1733-1736. DOI: 10.1016/j.jtho.2017.07.025. doi:10.1016/j.jtho.2017.07.025
[10]	Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-the ETOP NICOLAS trial[J]. Lung Cancer, 2019, 133:83-87. DOI: 10.1016/j.lungcan.2019.05.001. doi:S0169-5002(19)30441-6pmid:31200833
[11]	Miyamoto S, Nomura R, Sato K, et al. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage Ⅳ non-small-cell lung cancer[J]. Jpn J Clin Oncol, 2019, 49(2):160-164. DOI: 10.1093/jjco/hyy171. doi:10.1093/jjco/hyy171pmid:30452687
[12]	Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903. DOI: 10.1016/S1470-2045(17)30380-7. doi:S1470-2045(17)30380-7pmid:28551359
[13]	Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial[J]. JAMA Oncol, 2020, 6(6):848-855. DOI: 10.1001/jamaoncol.2019.6731. doi:10.1001/jamaoncol.2019.6731pmid:32077891
[14]	Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer: Hoosier cancer research network LUN 14-179[J]. Cancer, 2020, 126(19):4353-4361. DOI: 10.1002/cncr.33083. doi:10.1002/cncr.33083
[15]	Anouti B, Althouse S, Durm G, et al. Prognostic variables associated with improved outcomes in patients with stage Ⅲ NSCLC treated with chemoradiation followed by consolidation pembrolizumab: a subset analysis of a phase Ⅱ study from the Hoosier Cancer Research Network LUN 14-179[J]. Clin Lung Cancer, 2020, 21(3):288-293. DOI: 10.1016/j.cllc.2019.06.009. doi:S1525-7304(19)30151-2pmid:32143966
[16]	Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI: 10.1001/jamaoncol.2019.1478. doi:10.1001/jamaoncol.2019.1478
[17]	Welsh J, Menon H, Chen DW, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001001. DOI: 10.1136/jitc-2020-001001. doi:10.1136/jitc-2020-001001
[18]	Yan X, Zhao YT, Liu Y, et al. Case report: low-dose decitabine plus anti-PD-1 inhibitor camrelizumab for previously treated advanced metastatic non-small cell lung cancer[J]. Front Oncol, 2020, 10:558572. DOI: 10.3389/fonc.2020.558572. doi:10.3389/fonc.2020.558572
[19]	Wei Z, Yang X, Ye X, et al. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer[J]. J Cancer Res Ther, 2019, 15(7):1629-1634. DOI: 10.4103/jcrt.JCRT_990_19. doi:10.4103/jcrt.JCRT_990_19
[20]	Li W, Wei Z, Yang X, et al. Salvage therapy of reactive capillary hemangiomas: apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer[J]. J Cancer Res Ther, 2019, 15(7):1624-1628. DOI: 10.4103/jcrt.JCRT_997_19. doi:10.4103/jcrt.JCRT_997_19
[21]	Socinski MA, Özgüroğlu M, Villegas A, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage Ⅲ non-small-cell lung cancer (PACIFIC)[J]. Clin Lung Cancer, 2021, 22(6):549-561. DOI: 10.1016/j.cllc.2021.05.009. doi:10.1016/j.cllc.2021.05.009
[22]	Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6):824-835. DOI: 10.1016/S1470-2045(21)00149-2. doi:10.1016/S1470-2045(21)00149-2
[23]	Shaverdian N, Thor M, Shepherd AF, et al. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab[J]. Cancer Med, 2020, 9(13):4622-4631. DOI: 10.1002/cam4.3113. doi:10.1002/cam4.3113
[24]	Saito S, Abe T, Kobayashi N, et al. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer[J]. Clin Transl Radiat Oncol, 2020, 23:85-88. DOI: 10.1016/j.ctro.2020.05.006. doi:10.1016/j.ctro.2020.05.006
[25]	Inoue H, Ono A, Kawabata T, et al. Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer[J]. Invest New Drugs, 2020, 38(5):1612-1617. DOI: 10.1007/s10637-020-00917-2. doi:10.1007/s10637-020-00917-2
[26]	Lin SH, Lin Y, Yao LY, et al. Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC[J]. J Thorac Oncol, 2020, 15(2):248-257. DOI: 10.1016/j.jtho.2019.10.024. doi:10.1016/j.jtho.2019.10.024
[27]	Qin A, Rengan R, Lee S, et al. A pilot study of atezolizumab plus hypofractionated image guided radiation therapy for the treatment of advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):170-177. DOI: 10.1016/j.ijrobp.2019.10.047. doi:10.1016/j.ijrobp.2019.10.047
[28]	Nakashima K, Saruwatari K, Sato R, et al. Non-small-cell lung cancer with severe skin manifestations related to radiation recall dermatitis after atezolizumab treatment[J]. Intern Med, 2020, 59(9):1199-1202. DOI: 10.2169/internalmedicine.3937-19. doi:10.2169/internalmedicine.3937-19
[29]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. DOI: 10.1056/NEJMoa1801946. doi:10.1056/NEJMoa1801946
[30]	Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21):2020-2031. DOI: 10.1056/NEJMoa-1910231. doi:10.1056/NEJMoa-1910231
[31]	Boyer MJ, Gu L, Wang X, et al. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer[J]. Lung Cancer, 2016, 98:76-78. DOI: 10.1016/j.lungcan.2016.05.014. doi:10.1016/j.lungcan.2016.05.014
[32]	Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J]. Lancet Oncol, 2016, 17(3):299-308. DOI: 10.1016/S1470-2045(15)00544-6. doi:S1470-2045(15)00544-6pmid:26858122
[33]	Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer[J]. Ann Oncol, 2020, 31(5):609-618. DOI: 10.1016/j.annonc.2020.02.006. doi:S0923-7534(20)36041-5pmid:32201234

免疫治疗联合放化疗治疗非小细胞肺癌的临床研究进展

Clinical research progress of immunotherapy combined with chemoradiotherapy in the treatment of non-small cell lung cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献33

相关文章15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	钱晓涛, 石子宜, 胡格.Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[5]	吕璐, 孙鹏飞.肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[6]	崔腾璐, 孙鹏飞.鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201.
[8]	赵永瑞, 高莹, 陈怡东, 徐建堃.基于直线加速器的分次立体定向放疗对小体积脑转移瘤的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 138-143.
[9]	黄华玉, 龚虹云, 宋启斌.胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106.
[10]	张雨潇, 张连生, 李莉娟.新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125.
[11]	张碧霞, 丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[12]	吕璐, 孙鹏飞, 崔腾璐.子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[13]	马雪艳, 鲁历历, 孙鹏飞.免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[14]	李志磊, 罗加林.预测局部晚期直肠癌术前同步放化疗敏感性的生物学指标[J]. 国际肿瘤学杂志, 2022, 49(9): 564-567.
[15]	陈文莉, 倪志华, 陈红宇, 畅立圣, 范德生, 刘立伟, 丁青薇.免疫联合靶向治疗恶性腹膜间皮瘤1例[J]. 国际肿瘤学杂志, 2022, 49(8): 509-512.